Epigenetic Role of Long Non-coding RNAs in Multiple Myeloma

Area of Science:

• Molecular Biology
• Epigenetics
• Cancer Research

Background:

• Multiple myeloma (MM) is a hematological malignancy characterized by uncontrolled plasma cell proliferation.
• Epigenetic dysregulation plays a crucial role in MM pathogenesis and progression.
• Long non-coding RNAs (lncRNAs) are emerging as critical players in the epigenetic landscape of MM.

Purpose of the Study:

• To explore the role of lncRNAs as epigenetic regulators in multiple myeloma (MM).
• To elucidate the dual function of lncRNAs in the epigenetic pathobiology of MM.
• To review novel therapeutic strategies targeting lncRNAs and epigenetic modifications in MM.

Main Methods:

• Literature review of studies investigating lncRNAs and epigenetic mechanisms in MM.
• Analysis of lncRNA functions, including miRNA sponging and mRNA regulation.
• Examination of epigenetic modifications (e.g., methylation) affecting lncRNAs in MM.
• Review of preclinical and clinical data on lncRNA-targeted and epigenetic therapies.

Main Results:

• lncRNAs are critical for MM cell proliferation, progression, and drug resistance.
• Specific lncRNAs (e.g., MEG3, GAS5, H19) exhibit promoter hypermethylation, while MALAT1 shows hypomethylation.
• Targeting lncRNAs with siRNA, ASO, or CRISPR-Cas9 demonstrates preclinical efficacy.
• Epigenetic therapies (DNMTi, HDACi) combined with chemotherapy show promise in relapsed/refractory MM.

Conclusions:

• lncRNAs are pivotal epigenetic regulators in MM, influencing disease progression and biology.
• Targeting the lncRNA-epigenetic axis offers novel therapeutic avenues for MM.
• Integrating epigenetic strategies with conventional treatments may enhance MM therapeutic efficacy.